ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide protection through 5-6 months, with the same 105 mg dose regardless of weight.
It provides an additional preventive option to help protect newborns and infants born during or entering their first RSV season.
As RSV continues to cause infant hospitalisation and serious respiratory conditions, the HSA’s approval of ENFLONSIA™ reflects a continuing drive for preventive care and improving patient outcomes.
ENFLONSIA™ (clesrovimab) is now available for administration by the relevant health care providers in Singapore.
He added, “Clinical developments in this space provide us more ways to protect infants from RSV.
Singapore becomes first APAC market to approve MSD's Enflonsia for infant RSV prevention
June 2, 2026 | Tuesday | News
ENFLONSIA is a preventive monoclonal antibody designed to protect infants against a spectrum of RSV disease severity
MSD, trade name of Merck & Co., Inc., Rahway, N.J., USA, has announced that the Health Sciences Authority (HSA) of Singapore has approved ENFLONSIA (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season.
ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide protection through 5-6 months, with the same 105 mg dose regardless of weight. It provides an additional preventive option to help protect newborns and infants born during or entering their first RSV season.
As RSV continues to cause infant hospitalisation and serious respiratory conditions, the HSA’s approval of ENFLONSIA™ reflects a continuing drive for preventive care and improving patient outcomes. Singapore is the first market in Asia Pacific to receive approval for ENFLONSIA™.
ENFLONSIA™ (clesrovimab) is now available for administration by the relevant health care providers in Singapore.
“Infections from RSV can result in serious respiratory conditions in young children, including bronchiolitis and pneumonia,” said Assistant Professor Yeo Kee Thai, Senior Consultant, Department of Neonatology, KK Women's and Children’s Hospital. He added, “Clinical developments in this space provide us more ways to protect infants from RSV. This is crucial as we strengthen our preventive efforts to minimise the impact of the virus on babies.”
“RSV remains a significant cause of hospitalisation for infants in Singapore and globally. Beyond acute illness, RSV infection in early life has also been associated with a higher risk of subsequent respiratory morbidity, including recurrent wheezing and the development of asthma in childhood. Given the disease burden, we must continue to drive RSV prevention as a public health priority,” said Dr Jenny Tang, Senior Consultant paediatrician at SBCC Baby & Child Clinic.
